Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,059 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
Andorra M, Freire A, Zubizarreta I, de Rosbo NK, Bos SD, Rinas M, Høgestøl EA, de Rodez Benavent SA, Berge T, Brune-Ingebretse S, Ivaldi F, Cellerino M, Pardini M, Vila G, Pulido-Valdeolivas I, Martinez-Lapiscina EH, Llufriu S, Saiz A, Blanco Y, Martinez-Heras E, Solana E, Bäcker-Koduah P, Behrens J, Kuchling J, Asseyer S, Scheel M, Chien C, Zimmermann H, Motamedi S, Kauer-Bonin J, Brandt A, Saez-Rodriguez J, Alexopoulos LG, Paul F, Harbo HF, Shams H, Oksenberg J, Uccelli A, Baeza-Yates R, Villoslada P. Andorra M, et al. Among authors: paul f. J Neurol. 2024 Mar;271(3):1133-1149. doi: 10.1007/s00415-023-12132-z. Epub 2023 Dec 22. J Neurol. 2024. PMID: 38133801 Free PMC article.
Failure of natalizumab to prevent relapses in neuromyelitis optica.
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Kleiter I, et al. Among authors: paul f. Arch Neurol. 2012 Feb;69(2):239-45. doi: 10.1001/archneurol.2011.216. Arch Neurol. 2012. PMID: 22332191
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.
International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium. International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu, et al. Cell. 2019 Jun 27;178(1):262. doi: 10.1016/j.cell.2019.06.016. Cell. 2019. PMID: 31251915 Free PMC article. No abstract available.
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
Frahm N, Ellenberger D, Stahmann A, Fneish F, Lüftenegger D, Salmen HC, Schirduan K, Schaak TPA, Flachenecker P, Kleinschnitz C, Paul F, Krefting D, Zettl UK, Peters M, Warnke C. Frahm N, et al. Among authors: paul f. Ther Adv Neurol Disord. 2024 Mar 29;17:17562864241239740. doi: 10.1177/17562864241239740. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38560408 Free PMC article.
Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
Cortese R, Battaglini M, Prados F, Gentile G, Luchetti L, Bianchi A, Haider L, Jacob A, Palace J, Messina S, Paul F, Marignier R, Durand-Dubief F, de Medeiros Rimkus C, Apostolos Pereira SL, Sato DK, Filippi M, Rocca MA, Cacciaguerra L, Rovira À, Sastre-Garriga J, Arrambide G, Liu Y, Duan Y, Gasperini C, Tortorella C, Ruggieri S, Amato MP, Ulivelli M, Groppa S, Grothe M, Llufriu S, Sepulveda M, Lukas C, Bellenberg B, Schneider R, Sowa P, Celius EG, Pröbstel AK, Granziera C, Yaldizli Ö, Müller J, Stankoff B, Bodini B, Barkhof F, Ciccarelli O, De Stefano N; MAGNIMS Study Group. Cortese R, et al. Among authors: paul f. Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951. Online ahead of print. Ann Neurol. 2024. PMID: 38780377
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Among authors: paul f. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.
Jarius S, Ringelstein M, Schanda K, Ruprecht K, Korporal-Kuhnke M, Viehöver A, Hümmert MW, Schindler P, Endmayr V, Gastaldi M, Trebst C, Franciotta D, Aktas O, Höftberger R, Haas J, Komorowski L, Paul F, Reindl M, Wildemann B. Jarius S, et al. Among authors: paul f. J Neurol. 2024 Apr 13. doi: 10.1007/s00415-024-12285-5. Online ahead of print. J Neurol. 2024. PMID: 38609667
1,059 results